Improving efficiency with EBA chromatography

Richter-Helm BioLogics has announced that it will be improving the efficiency of its downstream processing capabilities by using 2nd Generation Expanded Bed Adsorption (EBA) chromatography that has been developed by the Danish company Upfront Chromatography.

According to a statement from the company, using 2nd generation EBA chromatography with a high titre antibody fragment secreting and a high-cell-density E.coli expression system resulted in a 60% improvement in product yield compared with conventional clarification processes.

"The manufacturing process with EBA chromatography required less facility time, allowing us to either increase the batch number or be operationally more flexible. The flexibility is of particular importance for busy contract manufacturing sites," says Dr Timo May, the company’s head of Downstream Processing. "It is a simple and robust technology with a high degree of capability. Companies can save significant costs if EBA chromatography is implemented into downstream processes at an early stage of a product's clinical development."

The company claims that implementation of EBA chromatography means that filtration steps, especially Cross-Flow-Filtration, are not necessary, which means that the company has also reported a 56% reduction in processing time in the cGMP suites without a loss in product quality.